GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TNF Pharmaceuticals Inc (LTS:0A8D) » Definitions » Research & Development

TNF Pharmaceuticals (LTS:0A8D) Research & Development : $5.27 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is TNF Pharmaceuticals Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. TNF Pharmaceuticals's Research & Development for the three months ended in Sep. 2024 was $0.71 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was $5.27 Mil.

TNF Pharmaceuticals Research & Development Historical Data

The historical data trend for TNF Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TNF Pharmaceuticals Research & Development Chart

TNF Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Research & Development
2.47 6.75 9.07 7.87

TNF Pharmaceuticals Quarterly Data
Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.91 2.96 1.20 0.40 0.71

TNF Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TNF Pharmaceuticals  (LTS:0A8D) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

TNF Pharmaceuticals Research & Development Related Terms

Thank you for viewing the detailed overview of TNF Pharmaceuticals's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

TNF Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TNF Pharmaceuticals Inc (LTS:0A8D) » Definitions » Research & Development
Comparable Companies
KTTA ARTL SLXN ENVB PHIO AZTR VRPX TTNP PKTX HEPA VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
TNFA:USA
Address
855 North Wolfe Street, Suite 601, Baltimore, MD, USA, 21205
Website
https://tnfpharma.com
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.

TNF Pharmaceuticals Headlines

No Headlines